
https://www.science.org/content/blog-post/car-t-follow
# CAR-T Follow Up (September 2015)

## 1. SUMMARY

The September 2015 article discusses early long-term follow-up results from the Novartis/University of Pennsylvania CAR-T cell therapy trial for leukemia patients. The key finding reported was that patients who achieved complete remission appeared to maintain their cure - the first patient had remained leukemia-free for five years at the time of publication. 

The trial involved 14 patients total: 8 responded to treatment, with 4 achieving complete remissions and 4 showing partial responses lasting months, while 6 patients showed no response at all. The article highlighted that non-responders failed because their modified T-cells didn't expand in vivo, though the reasons remained unclear. The author noted that multiple companies (Novartis, Juno, Kite) were working to extend CAR-T to more tumor types and scale production, while emphasizing the challenge of finding safe tumor-specific antigens for solid tumors to avoid devastating off-target immune attacks on healthy tissues.

## 2. HISTORY

The period following this 2015 article marked a watershed moment for CAR-T therapy commercialization and clinical validation:

**Regulatory Approvals:** In August 2017, Novartis's Kymriah (tisagenlecleucel) became the first CAR-T therapy approved by the FDA for pediatric and young adult B-cell acute lymphoblastic leukemia. Just months later, Gilead's Yescarta (axi-cel) gained FDA approval for adult large B-cell lymphoma. By 2022, six CAR-T therapies had received FDA approval.

**Clinical Outcomes:** Real-world efficacy largely validated the early promise. Kymriah demonstrated 83% overall remission rates in its pivotal trial, with many patients maintaining responses for years. However, significant challenges emerged: cytokine release syndrome (CRS) affected approximately 70-90% of patients, requiring sophisticated management protocols. Treatment-related deaths occurred, though rates decreased with better supportive care.

**Commercial Performance:** The therapies launched with high price tags ($373,000-$475,000 per treatment) but faced manufacturing and accessibility challenges. Patient slots were limited by complex logistics requiring apheresis facilities, specialized manufacturing, and qualified treatment centers. Uptake grew gradually rather than explosively.

**Industrial Consolidation:** Juno Therapeutics experienced setbacks when its lead candidate JCAR015 was halted in 2016 after five patient deaths from cerebral edema, ultimately leading to Celgene's acquisition in 2018 and later Bristol-Myers Squibb's purchase of Celgene. Kite Pharma was acquired by Gilead for $11.9B in 2017, indicating major pharma's confidence in the technology.

**Scientific Expansion:** By 2022, CAR-T research expanded beyond blood cancers to target multiple myeloma (with BCMA-targeting therapies like Abecma and Carvykti showing efficacy) and early-stage solid tumor trials, though solid tumor success remained limited due to the antigen-targeting challenges highlighted in the original article.

## 3. PREDICTIONS

- **Prediction:** The article suggested that extending CAR-T to more tumor classes and making it scalable were "the biggest prizes," with the second challenge being "big" and the first "even bigger."

**Reality:** This prediction proved remarkably accurate. CAR-T achieved spectacular success in blood cancers but struggled significantly in solid tumors due to the antigen-hunting challenges the author mentioned. Seven years later, while six approved CAR-T therapies existed, all targeted hematological malignancies (leukemias, lymphomas, and multiple myeloma). Solid tumor CAR-T trials generally showed disappointing results due to tumor heterogeneity, immunosuppressive microenvironments, and the lack of truly tumor-specific antigens that wouldn't attack healthy tissues, exactly as the author warned about avoiding "ripping out a couple of pounds of motor neurons."

- **Prediction:** The article noted that combining CAR-T with other therapies "hasn't really been tried yet" and figuring out why treatment failed in non-responders was key.

**Reality:** Combination strategies became a major focus, with CAR-T increasingly paired with checkpoint inhibitors, lymphodepleting chemotherapy, and other immunomodulators. However, the fundamental issue of T-cell expansion failure in some patients remained partially unsolved, though better lymphodepletion protocols and optimized T-cell manufacturing improved response rates.

- **Prediction:** Multiple companies (Novartis, Juno, Kite) working frantically on improvements.

**Reality:** The competitive landscape evolved as predicted, but with significant casualties - Juno's setbacks demonstrated the fragility of these programs, while Kite's acquisition showed the premium value large pharma placed on successful platforms.

## 4. INTEREST

Rating: **9/10**

This article demonstrates exceptional foresight about CAR-T's trajectory, accurately predicting both the spectacular success in blood cancers and the formidable challenges in solid tumors and scalability. The author's grasp of fundamental biological constraints (antigen specificity, tissue selectivity) made this analysis remarkably prescient and valuable for understanding CAR-T's subsequent seven-year evolution.

---

*Note: This analysis covers developments through approximately 2022, as the article was published in 2015 and a comprehensive assessment of "what happened after" would encompass roughly this timeframe for meaningful clinical and commercial outcomes.*


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150904-car-t-follow.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_